Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations
We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?